| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jeffrey I. Weitz | Q29561411 |
| P2860 | cites work | Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030 | Q39513006 |
| Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence | Q40310174 | ||
| Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge | Q41682626 | ||
| The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group | Q42542885 | ||
| Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
| Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial | Q44274506 | ||
| Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials | Q45139213 | ||
| Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin | Q46378061 | ||
| Extended use of dabigatran, warfarin, or placebo in venous thromboembolism | Q46848170 | ||
| Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty | Q46889469 | ||
| Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997-2004. | Q47799510 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism | Q49168967 | ||
| Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial | Q49173302 | ||
| Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy | Q73286594 | ||
| Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective | Q83085499 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials | Q83420277 | ||
| Apixaban for extended treatment of venous thromboembolism | Q85631280 | ||
| The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective | Q86685972 | ||
| Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin | Q87211864 | ||
| Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 | ||
| Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632872 | ||
| Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 | ||
| Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis | Q27027477 | ||
| A specific antidote for dabigatran: functional and structural characterization | Q27684149 | ||
| Dabigatran versus warfarin in patients with mechanical heart valves | Q28297637 | ||
| 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association | Q29614695 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). | Q33269104 | ||
| Apixaban or enoxaparin for thromboprophylaxis after knee replacement | Q34018819 | ||
| Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review | Q34130081 | ||
| Natural history of venous thromboembolism | Q34207019 | ||
| Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q34252907 | ||
| Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial | Q34267248 | ||
| A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa | Q34330708 | ||
| Dabigatran and postmarketing reports of bleeding | Q34332588 | ||
| Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. | Q34626105 | ||
| Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry | Q34646508 | ||
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism | Q34655742 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752573 | ||
| Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations | Q36900432 | ||
| Underuse of oral anticoagulants in atrial fibrillation: a systematic review | Q37770666 | ||
| Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control | Q37995402 | ||
| Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants | Q38065318 | ||
| New oral anticoagulants: comparative pharmacology with vitamin K antagonists | Q38071973 | ||
| Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis | Q38439334 | ||
| Management and outcomes of major bleeding during treatment with dabigatran or warfarin | Q38443753 | ||
| Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial | Q38469560 | ||
| P921 | main subject | anticoagulant | Q215118 |
| anticoagulation | Q63279445 | ||
| edoxaban tosylate | Q27158827 | ||
| P304 | page(s) | 93 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | F1000prime reports | Q27724626 |
| P1476 | title | Expanding use of new oral anticoagulants | |
| P478 | volume | 6 |
| Q28087744 | A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? |
| Q48189279 | Anticoagulation for the Pregnant Patient with a Mechanical Heart Valve, No Perfect Therapy: Review of Guidelines for Anticoagulation in the Pregnant Patient. |
| Q38429854 | Blood pressure control versus atrial fibrillation management in stroke prevention |
| Q41683411 | Exploring potential anticoagulant drug formulations using thrombin generation test. |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q38935933 | Lumbar puncture in patients using anticoagulants and antiplatelet agents. |
| Q26801895 | Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management |
| Q38602484 | Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors |
| Q89822698 | Spontaneous hemothorax as an adverse effect of rivaroxaban treatment |
Search more.